Karyopharm Therapeutics CEO Michael Kauffman's 2019 pay jumps 42% to $3.2M
Karyopharm Therapeutics reports 2019 executive compensation
By ExecPay News
Published: April 7, 2021
Karyopharm Therapeutics reported fiscal year 2019 executive compensation information on April 7, 2021.
In 2019, four executives at Karyopharm Therapeutics received on average a compensation package of $2.2M, a 17% increase compared to previous year.
Average pay of disclosed executives at Karyopharm Therapeutics
Michael G. Kauffman, Chief Executive Officer, received $3.2M in total, which increased by 42% compared to 2018. 46% of Kauffman's compensation, or $1.5M, was in option awards. Kauffman also received $364K in non-equity incentive plan, $567K in salary, $803K in stock awards, as well as $12K in other compensation.
Sharon Shacham, Chief Scientific Officer, received a compensation package of $3M, which increased by 45% compared to previous year. 49% of the compensation package, or $1.5M, was in option awards.
Christopher B. Primiano, General Counsel, earned $1.6M in 2019, a 7% increase compared to previous year.
Michael Mason, Chief Financial Officer, received $957K in 2019.
Related executives
You may also like
Source: SEC filing on April 7, 2021.